BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 17664483)

  • 1. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.
    Wick A; Felsberg J; Steinbach JP; Herrlinger U; Platten M; Blaschke B; Meyermann R; Reifenberger G; Weller M; Wick W
    J Clin Oncol; 2007 Aug; 25(22):3357-61. PubMed ID: 17664483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of protracted daily temozolomide for low-grade gliomas in adults.
    Kesari S; Schiff D; Drappatz J; LaFrankie D; Doherty L; Macklin EA; Muzikansky A; Santagata S; Ligon KL; Norden AD; Ciampa A; Bradshaw J; Levy B; Radakovic G; Ramakrishna N; Black PM; Wen PY
    Clin Cancer Res; 2009 Jan; 15(1):330-7. PubMed ID: 19118062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma.
    Han SJ; Rolston JD; Molinaro AM; Clarke JL; Prados MD; Chang SM; Berger MS; DeSilva A; Butowski NA
    Neuro Oncol; 2014 Sep; 16(9):1255-62. PubMed ID: 24670608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).
    Brandes AA; Tosoni A; Cavallo G; Bertorelle R; Gioia V; Franceschi E; Biscuola M; Blatt V; Crinò L; Ermani M;
    Br J Cancer; 2006 Nov; 95(9):1155-60. PubMed ID: 17024124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.
    Weiler M; Hartmann C; Wiewrodt D; Herrlinger U; Gorlia T; Bähr O; Meyermann R; Bamberg M; Tatagiba M; von Deimling A; Weller M; Wick W
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):670-6. PubMed ID: 19836157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.
    Galldiks N; Berhorn T; Blau T; Dunkl V; Fink GR; Schroeter M
    J Neurooncol; 2013 Apr; 112(2):209-15. PubMed ID: 23299464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
    Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M
    J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide in the treatment of recurrent malignant glioma.
    Chang SM; Theodosopoulos P; Lamborn K; Malec M; Rabbitt J; Page M; Prados MD
    Cancer; 2004 Feb; 100(3):605-11. PubMed ID: 14745879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.
    Herrlinger U; Rieger J; Koch D; Loeser S; Blaschke B; Kortmann RD; Steinbach JP; Hundsberger T; Wick W; Meyermann R; Tan TC; Sommer C; Bamberg M; Reifenberger G; Weller M
    J Clin Oncol; 2006 Sep; 24(27):4412-7. PubMed ID: 16983109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Temozolomide in the treatment of recurrent malignant glioma].
    Kobayashi H; Sawamura Y; Ishii N; Murata J; Iwasaki Y
    No Shinkei Geka; 2006 Dec; 34(12):1241-7. PubMed ID: 17154070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of temozolomide using an extended continuous oral schedule.
    Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
    Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.
    Taal W; Segers-van Rijn JM; Kros JM; van Heuvel I; van der Rijt CC; Bromberg JE; Sillevis Smitt PA; van den Bent MJ
    J Neurooncol; 2012 May; 108(1):195-200. PubMed ID: 22396071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.
    Tosoni A; Franceschi E; Ermani M; Bertorelle R; Bonaldi L; Blatt V; Brandes AA
    J Neurooncol; 2008 Sep; 89(2):179-85. PubMed ID: 18431544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients.
    Silvani A; Eoli M; Salmaggi A; Lamperti E; Maccagnano E; Broggi G; Boiardi A
    J Neurooncol; 2004 Jan; 66(1-2):203-8. PubMed ID: 15015788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas.
    Balmaceda C; Peereboom D; Pannullo S; Cheung YK; Fisher PG; Alavi J; Sisti M; Chen J; Fine RL
    Cancer; 2008 Mar; 112(5):1139-46. PubMed ID: 18246536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.
    Chinot OL; Barrié M; Fuentes S; Eudes N; Lancelot S; Metellus P; Muracciole X; Braguer D; Ouafik L; Martin PM; Dufour H; Figarella-Branger D
    J Clin Oncol; 2007 Apr; 25(12):1470-5. PubMed ID: 17442989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of palliative treatment with temozolomide in patients with high-grade gliomas.
    Ziobro M; Rolski J; Grela-Wojewoda A; Zygulska A; Niemiec M
    Neurol Neurochir Pol; 2008; 42(3):210-5. PubMed ID: 18651326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
    Khan RB; Raizer JJ; Malkin MG; Bazylewicz KA; Abrey LE
    Neuro Oncol; 2002 Jan; 4(1):39-43. PubMed ID: 11772431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
    Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y
    Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temozolomide for recurrent low-grade spinal cord gliomas in adults.
    Chamberlain MC
    Cancer; 2008 Sep; 113(5):1019-24. PubMed ID: 18615600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.